<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547546</url>
  </required_header>
  <id_info>
    <org_study_id>GO28070</org_study_id>
    <secondary_id>2011-004479-35</secondary_id>
    <nct_id>NCT01547546</nct_id>
  </id_info>
  <brief_title>A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma</brief_title>
  <official_title>An Open-label, Phase I, Dose-escalation Study Evaluating the Safety and Tolerability of GDC-0084 Administered to Patients With Progressive or Recurrent High-grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and&#xD;
      tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with&#xD;
      progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study.&#xD;
      Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve</measure>
    <time_frame>Pre- and post-dose Days 1, 8, 15, 22 and 29 Cycle 1, Day 1 every following Cycle until 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response rate, tumor assessments according to Response Assessment in Neuro-Oncology (RANO)</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Glioblastoma, Glioma</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC-0084</intervention_name>
    <description>Multiple doses</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients, &gt;/= 18 years of age&#xD;
&#xD;
          -  Interval of at least 12 weeks from completion of adjuvant radiotherapy for gliomas to&#xD;
             study entry&#xD;
&#xD;
          -  Karnofsky Performance Status of &gt;/= 70 at screening&#xD;
&#xD;
          -  Confirmed measurable disease per RANO&#xD;
&#xD;
          -  Adequate hematologic and organ function&#xD;
&#xD;
        Patients enrolled in Stage 1:&#xD;
&#xD;
          -  Histologically documented recurrent or progressive high-grade gliomas (WHO Grade&#xD;
             III-IV)&#xD;
&#xD;
          -  Prior treatment with at least one regimen for gliomas (radiotherapy with or without&#xD;
             chemotherapy for Grade III gliomas and radiotherapy with chemotherapy for Grade IV&#xD;
             gliomas) and/or not considered to be a candidate for regimens known to provide&#xD;
             clinical benefit&#xD;
&#xD;
        Patients enrolled in Stage 2:&#xD;
&#xD;
          -  Histologically documented recurrent or progressive glioblastoma (WHO Grade IV gliomas)&#xD;
&#xD;
          -  Prior treatment with one or two regimens for glioblastoma (with the initial regimen&#xD;
             consisting of radiotherapy with chemotherapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with anti-tumor therapy (approved or experimental) within 4 weeks prior to&#xD;
             initiation of study drug&#xD;
&#xD;
          -  Requirement for anticoagulants such as warfarin or any other warfarin-derivative&#xD;
             anticoagulants; low-molecular-weight heparin is permitted&#xD;
&#xD;
          -  Any contraindication to MRI examination&#xD;
&#xD;
          -  Evidence of Grade &gt;/= 1 intracranial hemorrhage&#xD;
&#xD;
          -  Active congestive heart failure or ventricular arrhythmia requiring medication&#xD;
&#xD;
          -  Clinically significant history of liver disease, including viral or other hepatitis,&#xD;
             current alcohol abuse or cirrhosis&#xD;
&#xD;
          -  Unresolved toxicity from prior therapy with the exception of lymphopenia (for patients&#xD;
             with prior temozolomide) and alopecia&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>GDC-0084</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

